TITLE

BioWorld Stock Report For Public Biotechnology Companies

PUB. DATE
May 2013
SOURCE
BioWorld Insight;5/13/2013, Vol. 21 Issue 20, p29
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
A table is presented which lists the stock position of public biotechnology companies on May13, 2013 including Ampio Pharmaceuticals Inc. in Greenwood Village, Colombia, Cyclacel Pharmaceuticals Inc. in Berkeley Heights, New Jersey, and Biocryst Pharmaceuticals Inc. in Durham, North Carolina.
ACCESSION #
87619301

 

Related Articles

  • BioWorld Stock Report For Public Biotechnology Companies.  // BioWorld Insight;9/17/2012, Vol. 20 Issue 38, p14 

    A chart is presented listing the stocks for public biotechnology companies in 2012.

  • BioWorld Stock Report For Public Biotechnology Companies.  // BioWorld Insight;1/ 2/2013, Vol. 21 Issue 1, p22 

    A chart is presented that depicts the BioWorld Stock Report for public biotechnology companies including 3S Bio, Acadia Pharma, and Albany Molecular.

  • ATM cash for biotechs. Orelli, Brian // Nature Biotechnology;Oct2011, Vol. 29 Issue 10, p856 

    The article reports that U.S.-based biotechnology companies Somaxon Pharmaceuticals and BioCryst Pharmaceuticals raised capital through at-the-market (ATM) offerings.

  • Cyclacel Seeks to Raise $22M for AML Drug.  // Bioworld Week;10/11/2010, Vol. 18 Issue 41, p3 

    The article reports on the plan of Cyclacel Pharmaceuticals Inc. in raising their sale of stock and warrants for the acute myeloid leukemia (AML) drug up to 22.1 million U.S. dollars.

  • Biotech Companies.  // Inside Tucson Business;7/6/2011, Vol. 21 Issue 6, p7 

    A chart is presented which lists biotech companies in Arizona including Ventana Medical Systems Inc., SynCardia Systems Inc., and Thayer Medical Corp.

  • Drug tested for the tx of psoriasis.  // Dermatology Times;Dec95, Vol. 16 Issue 12, p4 

    Reports on BioCryst Pharmaceuticals Incorporated initiating an expanded Phase II clinical trial for the topical formulation of its lead drug, BCX-34, for the treatment of psoriasis. Primary clinical endpoints; Clinical trial details.

  • BioCryst Presents Results from Its BCX4208 Gout Program at the Annual European Congress of Rheumatology.  // Biomedical Market Newsletter;6/7/2012, Vol. 21, p1 

    The article informs that the European League Against Rheumatism will be hosting the Annual European Congress of Rheumatology from June 7-8, 2012 in Berlin, Germany will feature a presentation by BioCryst Pharmaceuticals Inc.

  • BioCryst Stock Takes a Hit as Peramivir Trial Extended.  // Bioworld Week;1/17/2011, Vol. 19 Issue 3, p5 

    The article reports on the 6.7 percent fall of the stock of BioCryst Pharmaceuticals Inc. after the statement of Research Triangle Park that it extends the enrollment period for a trial of peramivir for hospitalized influenza patients.

  • BioCryst Pharmaceuticals to Announce 3rd Qtr 2011 Financial Results on Nov 2 2011.  // Biomedical Market Newsletter;10/24/2011, Vol. 21, p107 

    The article offers information on the conference call and webcast to be hosted by BioCryst Pharmaceuticals Inc. on November 2, 2011

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics